Altered Microglia-Neuron Crosstalk and Regional Heterogeneity in Alzheimer's Disease Revealed by Single-Nucleus RNA

Zhenqi Yang1, Mingzhao Zhang1, Weijia Zhi1

  • 1Beijing Institute of Radiation Medicine, 27 Taiping Road, Beijing 100850, China.

Insights

Alzheimer's disease involves region-specific microglia-neuron communication. THY1 dysregulation is a common factor across brain regions, offering a potential therapeutic target for modulating microglial function.

Area of Science:

  • Neuroscience
  • Immunology
  • Genomics

Background:

  • Alzheimer's disease (AD) is the leading cause of dementia, characterized by cognitive decline.
  • Microglia-neuron interactions are increasingly recognized as critical in AD pathogenesis.
  • Regional heterogeneity in microglial responses complicates understanding AD progression.

Purpose of the Study:

  • To investigate the region-specific nature of microglia-neuron crosstalk in Alzheimer's disease.
  • To identify molecular mechanisms underlying disease-associated microglia (DAM) activation.
  • To explore potential therapeutic targets for modulating microglial function in AD.

Main Methods:

  • Integrated human single-nucleus RNA sequencing data from prefrontal cortex, hippocampus, and occipital lobe.
  • Delineated microglial subtypes and their activation trajectories.
  • Analyzed region-specific microglia-neuron signaling pathways.

Main Results:

  • Identified four microglial subtypes and a pseudotime trajectory towards the DAM phenotype.
  • Discovered coordinated downregulation of inhibitory factors and upregulation of immune programs drive DAM state.
  • Revealed distinct regional communication patterns: PFC/OL use THY1-ITGAX/ITGB2, HPC uses PTPRM.
  • THY1 dysregulation showed strong correlation with AD pathology across all studied regions.

Conclusions:

  • Microglia-neuron crosstalk in AD exhibits both regional specificity and commonalities.
  • THY1 is identified as a potential key mediator in AD-related microglia-neuron interactions.
  • Targeting THY1 may offer a therapeutic strategy to modulate microglial function in Alzheimer's disease.